The Clorox Company (CLX)
NYSE · Consumer Staples · market cap 13.02B
Share price
$85.00
At the last nightly close
Intrinsic value
n/a
No valuation the available data can support for this company.
Margin of safety
n/a
Requires an intrinsic value and a price.
EV / EBIT
n/a
Not ranked: short history.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.
The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2026-FY | 6.72B | 886.0M | 587.0M | 4.82 | 405.0M |
| 2025-FY | 7.10B | 1.18B | 810.0M | n/a | 761.0M |
| 2024-FY | 7.09B | 723.0M | 280.0M | 2.26 | 483.0M |
| 2023-FY | 7.39B | 823.0M | 149.0M | 1.21 | 930.0M |
| 2022-FY | 7.11B | n/a | 462.0M | 3.73 | 535.0M |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on CLX.
Run the board on CLX10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.